Table 1 Adapted from [66]
From: What’s new in multidrug-resistant pathogens in the ICU?
Company | Product | Class/structure | Mechanism of action | Lead indication |
|---|---|---|---|---|
Actelion Ltd. (SIX:ATLN) | Cadazolid (179811) | Oxazolidinone–quinolone hybrid | Inhibit DNA replication and protein synthesis | CDAD |
Affinium Pharmaceuticals Ltd. | AFN-1252 | FabI enoyl-(acyl carrier protein) reductase inhibitor | Inhibit fabI | ABSSSI |
CrystalGenomics Inc. (KOSDAQ:83790) | CG400549 | FabI enoyl-(acyl carrier protein) reductase inhibitor | Inhibit fabI | Complicated ABSSSI |
GlaxoSmithKline plc(LSE:GSK; NYSE:GSK) | GSK1322322 | Peptide deformylase (PDF) inhibitor | Inhibit PDF | Bacterial infection |
Furiex Pharmaceuticals Inc. (NASDAQ:FURX)/Johnson & Johnson (NYSE:JNJ) | JNJ-32729463 (JNJ-Q2) | Fluoroquinolone | Inhibit DNA replication | ABSSSI, CAP |
Nabriva Therapeutics AG/Forest Laboratories Inc. (NYSE:FRX) | BC-3781 | Pleuromutilin | Inhibit protein synthesis | ABSSSI |
Novartis AG (NYSE:NVS) | LFF571 | Thiopeptide | Inhibit protein synthesis | CDAD |
PolyMedix Inc. (OTCBB:PYMX) | Brilacidin (PMX-30063) | Defensin mimetics | Membrane lysis | ABSSSI |
Rib-X Pharmaceuticals Inc. | Radezolid (RX-1741) | Oxazolidinone | Inhibit protein synthesis | CAP |
Tetraphase Pharmaceuticals Inc. | Eravacycline (TP-434) | Tetracycline | Inhibit protein synthesis | cIAI |
Theravance Inc. (NASDAQ:THRX) | TD-1792 | Beta-lactam-glycopeptide hybrid | Inhibit cell wall synthesis | Gram-positive cSSSI |
Wockhardt Ltd. (BSE:532300) | WCK 771 | Fluoroquinolone | Inhibit DNA replication | S. aureus |
Wockhardt Ltd. (BSE:532300) | WCK 2349 | Fluoroquinolone | Inhibit DNA replication | Gram-positive cSSSI |
Nanotherapeutics Inc. | Ramoplanin | Lipoglycodepsipeptide | Inhibit cell wall production | CDAD |
2 M BioTech L.P. | CBR-2092 | Rifamycin–quinolone hybrid | Inhibit DNA replication and RNA synthesis | S. aureus |
Achaogen Inc. | ACHN-975 | N-acetylglucosamine deacetylase (LpxC) inhibitor | Inhibit LpxC | Gram-negative |
aRigen Pharmaceuticals Inc./Green Cross Corp. | WAP-8294A2 | Depsipeptide | Disrupt membrane | MRSA |
Basilea Pharmaceutica AG (SIX:BSLN) | BAL30072 | Beta-lactam (monocyclic) | Inhibit cell wall synthesis | Gram-negative |
FAB Pharma S.A.S. | FAB001 (MUT056399) | FabI enoyl-(acyl carrier protein) reductase inhibitor | Inhibit fabI | S. aureus |
Kalidex Pharmaceuticals Inc. | KPI-10 | Fluoroquinolone | Inhibit DNA replication | Gram-negative and Gram-positive |
Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) | KRP-AM1977X | Quinolone | Inhibit DNA replication | Gram-positive |
MicuRx Pharmaceuticals Inc. | MRX-I | Oxazolidinone | Inhibit protein synthesis | Gram-positive |
Novacta Biosystems Ltd. | NVB302 | Lantibiotic | Inhibit cell wall synthesis | CDAD |
Rempex Pharmaceuticals Inc. | Carbavance (RPX7009/biapenem) | Beta-lactamase inhibitor with boron core (RPX7009); beta-lactam (biapenem) | Inhibit cell wall synthesis | Gram-negative |
Shionogi & Co. Ltd.(Tokyo:4507)/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) | S-649266 | Beta-lactam | Inhibit cell wall synthesis | CAP |
Tetraphase Pharmaceuticals Inc. | TP-2758 | Tetracycline | Inhibit protein synthesis | cUTI |